文献速递糖尿病

SGLT2i对2型糖尿病心肾结局影响的Meta分析

SGLT2 Inhibitors Reduce Heart Failure Hospitalization, Cardiovascular Death and Kidney Outcomes in Type 2 Diabetes: A Meta‐Analysis of Randomized Controlled Trials
RSS 订阅 · Diabetes, Obesity and Metabolism · 2026-10-13

结果显示SGLT2i可显著降低心衰住院或心血管死亡复合终点风险23%,并降低MACE、心衰住院及复合肾脏结局风险。研究支持将SGLT2i作为2型糖尿病的基础治疗药物。

要点

  • SGLT2i降低2型糖尿病患者心衰住院或心血管死亡复合终点风险23%。
  • 首次心衰住院风险降低29%,复合肾脏结局风险降低31%。
  • 基线心衰或动脉粥样硬化性心血管病状态不影响整体获益。

核心结论

  • SGLT2抑制剂在2型糖尿病患者中提供一致且有临床意义的心肾保护,覆盖广泛的心血管和肾脏风险谱。

研究设计与样本

  • 检索PubMed、Web of Science、Scopus和CENTRAL数据库,时间截至2026年5月15日。
  • 采用随机效应逆方差模型估算风险比及95%置信区间。

主要发现

  • 主要复合终点风险降低23%(HR:0.77,95% CI:0.73–0.81,p < 0.0001;I² = 0%)。
  • MACE风险降低14%(HR:0.86,95% CI:0.81–0.92),心血管死亡降低14%(HR:0.86,95% CI:0.79–0.93)。
  • 首次心衰住院风险降低29%(HR:0.71,95% CI:0.66–0.77),复合肾脏结局风险降低31%(HR:0.69,95% CI:0.60–0.79)。

关键数值与推荐

  • 基线心衰状态对主要终点无效应修饰(p交互 = 0.82),已确诊动脉粥样硬化性心血管病亦无效应修饰(p交互 = 0.46)。

临床怎么用

  • 支持内分泌科、心内科及基层医生将循证SGLT2i作为2型糖尿病的基础治疗药物积极起始使用。

局限性

  • ertugliflozin的效应估计值及肾脏结局的中度异质性需结合试验间临床差异和肾脏终点定义不统一进行解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

ABSTRACT Background Cardiovascular disease and chronic kidney disease are the principal drivers of morbidity and mortality in type 2 diabetes mellitus (T2DM). Sodium-glucose cotransporter-2 inhibitors (SGLT2i) have demonstrated cardiorenal benefits in landmark trials, yet cross-trial inconsistencies in cardiovascular mortality, renal endpoints and drug-specific effects leave the class-level estimates incompletely synthesized. Methods PubMed, Web of Science, Scopus and CENTRAL were searched from inception through 15 May 2026. Large placebo-controlled RCTs (≥ 1000 participants) and prespecified subgroup analyses in adults with T2DM were eligible. The primary outcome was the composite of first hospitalization for heart failure (HHF) or cardiovascular death (CV death). Secondary outcomes were 3-point major adverse cardiovascular events (MACE), CV DEATH, myocardial infarction (MI), stroke, first HHF and composite kidney outcomes. Hazard ratios (HRs) with 95% confidence intervals (CIs) were estimated using random-effects inverse-variance models. Results Fourteen studies (76 969 patients; 41 761 SGLT2i, 35 208 placebo) were included. SGLT2i reduced the primary composite by 23% (HR: 0.77, 95% CI: 0.73–0.81, p < 0.0001; I 2 = 0%), with no effect modification by baseline HF (p-interaction = 0.82) or established ASCVD (p-interaction = 0.46). MACE was reduced by 14% (HR: 0.86, 95% CI: 0.81–0.92), driven by significant reductions in CV DEATH (HR: 0.86, 95% CI: 0.79–0.93) and MI (HR: 0.88, 95% CI: 0.81–0.96), with no significant effect on stroke (HR: 0.93, 95% CI: 0.81–1.08). First, HHF was reduced by 29% (HR: 0.71, 95% CI: 0.66–0.77) and composite kidney outcomes by 31% (HR: 0.69, 95% CI: 0.60–0.79). Conclusions SGLT2i confer consistent and clinically meaningful cardiorenal protection in T2DM across the full spectrum of cardiovascular and renal risk. The ertugliflozin estimate and the moderate heterogeneity in kidney outcomes should be interpreted in the context of trial-level clinical differences and nonstandardized kidney endpoint definitions. These findings support proactive, guideline-concordant initiation of evidence-based SGLT2i agents by endocrinologists, cardiologists and primary care providers as foundational therapy in T2DM.

来源:Diabetes, Obesity and Metabolism,查看原文。版权归原作者所有。

引用

  1. Diabetes, Obesity and Metabolism:SGLT2 Inhibitors Reduce Heart Failure Hospitalization, Cardiovascular Death and Kidney Outcomes in Type 2 Diabetes: A Meta‐Analysis of Randomized Controlled Trials

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。